Biblio Discovery — Demo Discovery Service

20 results

Showing 1–20 · 0.77 seconds · RSS

Journal

Leukemia

Scopus

ISSN 0887-6924 · Springer Nature · 20 articles in the index

  1. Journal Article Full text

    The KMT2A recombinome of acute leukemias in 2023

    Claus Meyer; Patrizia Larghero; Bruno A. Lopes et al.

    Leukemia · 2023 · English · OpenAlex Scopus

    Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. Genomic breakpoints within…

  2. Journal Article Full text

    The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

    Joseph David Khoury; Éric Solary; Oussama Abla et al.

    Leukemia · 2022 · English · OpenAlex Scopus

    The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for…

  3. Journal Article Full text

    The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

    Rita Alaggio; Catalina Amador; Ioannis Anagnostopoulos et al.

    Leukemia · 2022 · English · OpenAlex Scopus

    Abstract We herein present an overview of the upcoming 5 th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the…

  4. Journal Article Full text

    LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    María‐Victoria Mateos; Katja Christina Weisel; Valerio De Stefano et al.

    Leukemia · 2022 · English · OpenAlex Scopus

    Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first…

  5. Journal Article Full text

    Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

    Hagop M. Kantarjian; Timothy P. Hughes; Richard A. Larson et al.

    Leukemia · 2021 · English · OpenAlex Scopus

    Abstract In the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative molecular response rates, lower rates of disease progression and CML-related death, and increased eligibility for…

  6. Journal Article Full text

    COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

    Per T Ljungman; Rafael de la Cámara; Małgorzata Mikulska et al.

    Leukemia · 2021 · English · OpenAlex Scopus

    This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH)…

  7. Journal Article Full text

    Molecular biology of Hodgkin lymphoma

    Marc A. Weniger; Ralf Küppers

    Leukemia · 2021 · English · OpenAlex Scopus

    Abstract Classical Hodgkin lymphoma (cHL) is unique among lymphoid malignancies in several key biological features. (i) The Hodgkin and Reed-Sternberg (HRS) tumor cells are rare among an extensive and complex microenvironment. (ii) They derive from B cells, but have largely lost the B-cell typical…

  8. Journal Article Full text

    T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments

    Naval Guastad Daver; Ahmad S. Alotaibi; Veit Bücklein et al.

    Leukemia · 2021 · English · OpenAlex Scopus

    Acute myeloid leukemia (AML) is a heterogeneous disease linked to a broad spectrum of molecular alterations, and as such, long-term disease control requires multiple therapeutic approaches. Driven largely by an improved understanding and targeting of these molecular aberrations, AML treatment has…

  9. Journal Article Full text

    Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies

    Julia Stomper; John Charles Rotondo; Gabriele Greve et al.

    Leukemia · 2021 · English · OpenAlex Scopus

    Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA methylation, thereby triggering the re-programming of tumor cells. The first-generation HMA azacitidine and decitabine have…

  10. Journal Article Full text

    Catch me if you can: how AML and its niche escape immunotherapy

    Sarah Tettamanti; Alice Pievani; Andrea Biondi et al.

    Leukemia · 2021 · English · OpenAlex Scopus

    In spite of the remarkable progress in basic and preclinical studies of acute myeloid leukemia (AML), the five-year survival rate of AML patients remains poor, highlighting the urgent need for novel and synergistic therapies. Over the past decade, increased attention has been focused on identifying…

  11. Journal Article Full text

    COVID-19 in persons with haematological cancers

    Wenjuan He; Lei Chen; Li Chen et al.

    Leukemia · 2020 · English · OpenAlex Scopus

  12. Journal Article Full text

    B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

    Nina D. Shah; Ajai Chari; Emma Scott et al.

    Leukemia · 2020 · English · OpenAlex Scopus

    Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all…

  13. Journal Article Full text

    Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future?

    Mariusz Z. Ratajczak; Janina Ratajczak

    Leukemia · 2020 · English · OpenAlex Scopus

    There are concepts in science that need time to overcome initial disbelief before finally arriving at the moment when they are embraced by the research community. One of these concepts is the biological meaning of the small, spheroidal vesicles released from cells, which are described in the…

  14. Journal Article Full text

    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus; Michele Baccarani; Richard T. Silver et al.

    Leukemia · 2020 · English · OpenAlex Scopus

    The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free…

  15. Journal Article Full text

    Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

    Tingyu Wen; Jinsong Wang; Yuankai Shi et al.

    Leukemia · 2020 · English · OpenAlex Scopus

    Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of…

  16. Journal Article Full text

    SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells

    Mariusz Z. Ratajczak; Magda Kucia

    Leukemia · 2020 · English · OpenAlex Scopus

    The scientific community faces an unexpected and urgent challenge related to the SARS-CoV-2 pandemic and is investigating the role of receptors involved in entry of this virus into cells as well as pathomechanisms leading to a cytokine "storm," which in many cases ends in severe acute respiratory…

  17. Journal Article Full text

    Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

    Nizar Jacques Bahlis; Meletios Athanasios Dimopoulos; Darrell J. White et al.

    Leukemia · 2020 · English · OpenAlex Scopus

    Abstract In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of disease progression or death by 63% and increased the overall response rate (ORR) versus Rd in relapsed/refractory multiple myeloma (RRMM). Updated efficacy and safety after >3 years of follow-up are…

  18. Journal Article Full text

    The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

    Felicitas La Rosée; Hinrich Bremer; Iris Gehrke et al.

    Leukemia · 2020 · English · OpenAlex Scopus

    Abstract A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to…